A Phase 3 interventional study of Monalizumab and Cetuximab in Squamous Cell Carcinoma of the Head and Neck, sponsored by AstraZeneca. Active, not recruiting at 127 sites in 23 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca — 4 open to participants now, 6 under way, 2 of them phase 3. Squamous Cell Carcinoma of Head and Neck · AstraZeneca.
Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2020, is one of 4 in phase 3, and was the 16th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →4 of the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, Japan and 1 more country
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 9 more countries
Ages 18+
AstraZeneca · Sites in United States, Austria, Belgium and 20 more countries
Ages 18–130
AstraZeneca · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 8 · Phase 3 4
First in 2003; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 370 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 78 across the 21 interventional studies, 412 across the 1 observational. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
1 of the studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06147037AstraZenecaA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck cancer
Participants with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who had prior immune checkpoint inhibitor and platinum-based chemotherapy treatment will be randomized in a 2:1 ratio to monalizumab and cetuximab or placebo and cetuximab. Efficacy and safety assessments will be performed periodically from the time of enrollment and throughout the study. Participants in all arms will continue therapy until progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. All Participants will be followed for survival after progression is confirmed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intravenous (IV) monalizumab 750 mg every two weeks (Q2W) and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 every one week (Q1W) until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
Drug: Monalizumab · Drug: Cetuximab
Participants will receieve IV placebo matched to monalizumab Q2W and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 Q1W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
Drug: Cetuximab · Other: Placebo
Participants will receive IV infusion of monalizumab as stated in arm description.
Also known as: IPH2201
Participants will receive IV infusion of cetuximab as stated in arm description.
Also known as: Erbitux
Participants will receive IV infusion of placebo as stated in arm description.
Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set
The OS is defined as time from the date of randomization until death due to any cause regardless of whether the participant withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization + 1). The OS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and hazard ratio (HR) and confidence intervals (CIs) from a stratified Cox proportional hazards model. Analyses were stratified on World Health Organization/ Eastern Cooperative Oncology Group performance status (WHO/ECOG PS) (0 or 1) and number of prior lines of therapy in recurrent or metastatic (R/M) setting (1 or 2).
Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Overall Survival in Full Analysis Set (FAS)
The OS is defined as time from the date of randomization until death due to any cause regardless of whether the participant withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization + 1). The OS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on HPV status (OPC HPV positive or HPV-unrelated), WHO/ECOG PS (0 or 1) and number of prior lines of therapy in R/M setting (1 or 2).
Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment in HPV-unrelated Analysis Set
PFS per RECIST 1.1 as assessed by the investigator is defined as time from randomization until date of RECIST 1.1-defined radiological progressive disease (PD) or death regardless of whether participant withdraws from therapy or received subsequent anticancer therapy prior to progression. PD: at least 20% increase in sum of diameters of target lesions (TLs), taking as reference the smallest sum on study (nadir) and sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing non-TLs (NTLs) or appearance of new lesions. PFS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on WHO/ECOG PS (0/1) and no. of prior lines of therapy in R/M setting.
Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Progression-Free Survival Per RECIST 1.1 by Investigator Assessment in FAS
PFS per RECIST 1.1 as assessed by the investigator is defined as time from randomization until date of RECIST 1.1-defined radiological progressive disease (PD) or death regardless of whether participant withdraws from therapy or received subsequent anticancer therapy prior to progression. PD: at least 20% increase in sum of diameters of target lesions (TLs), taking as reference the smallest sum on study (nadir) and sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. PFS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on HPV status, WHO/ECOG PS (0/1) and no. of prior lines of therapy in R/M setting.
Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Percentage of Participants With Objective Response (OR) Per RECIST 1.1 in HPV-unrelated Analysis Set
The OR is defined as the percentage of participants with at least one confirmed investigator-assessed response of complete response (CR) or partial response (PR) as assessed by RECIST 1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. Participants who had measurable disease at baseline per the site investigator were analyzed for this outcome.
Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Percentage of Participants With OR Per RECIST 1.1 in FAS
The OR is defined as the percentage of participants with at least one confirmed investigator-assessed response of CR or PR as assessed by RECIST 1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. Participants who had measurable disease at baseline per the site investigator were analyzed for this outcome.
Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Duration of Response (DoR) Per RECIST 1.1 in HPV-unrelated Analysis Set
The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as at least a 30% decrease in the SoDs of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in the SoDs of TLs, taking as reference the smallest previous SoDs (nadir) and the sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. The DoR was analyzed using Kaplan-Meier technique.
Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Duration of Response Per RECIST 1.1 in FAS
The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as at least a 30% decrease in the SoDs of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in the SoDs of TLs, taking as reference the smallest previous SoDs (nadir) and the sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. The DoR was analyzed using Kaplan-Meier technique.
Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.
Time frame: Day 1 through 21.4 months (maximum observed duration)
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs
Participants with abnormal laboratory parameters reported as TEAEs are reported. Laboratory analysis included hematology and clinical chemistry. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.
Time frame: Day 1 through 21.4 months (maximum observed duration)
Number of Participants With Abnormal Vital Signs Reported as TEAEs
Participants with abnormal vital signs (heart rate, blood pressure, temperature, and respiratory rate) reported as TEAEs are reported. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.
Time frame: Day 1 through 21.4 months (maximum observed duration)
Number of Participants With Electrocardiograms (ECGs) Reported as TEAEs
Participants with Abnormal ECGs reported as TEAEs are reported. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.
Time frame: Day 1 through 21.4 months (maximum observed duration)
The study was conducted at study sites located in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, France, Germany, Greece, Italy, Japan, Netherlands, Philippines, Poland, Portugal, Republic of Korea, Russia, Spain, Switzerland, Taiwan, United Kingdom, and United States of America.
| Milestone | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Started | 247 | 123 |
| Treated | 246 | 122 |
| Completed | 0 | 0 |
| Not completed | 247 | 123 |
| Withdrew: Death | 118 | 59 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Progressive disease | 0 | 1 |
| Withdrew: Study terminated by sponsor | 103 | 50 |
| Withdrew: Withdrawal by subject | 15 | 8 |
| Withdrew: Ongoing at data cut-off | 9 | 4 |
| Withdrew: Screen failure | 1 | 0 |
The OS is defined as time from the date of randomization until death due to any cause regardless of whether the participant withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization + 1). The OS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and hazard ratio (HR) and confidence intervals (CIs) from a stratified Cox proportional hazards model. Analyses were stratified on World Health Organization/ Eastern Cooperative Oncology Group performance status (WHO/ECOG PS) (0 or 1) and number of prior lines of therapy in recurrent or metastatic (R/M) setting (1 or 2).
| Months | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set | 8.8 (6.9 to 10.4) | 8.6 (6.0 to 14.5) |
The OS is defined as time from the date of randomization until death due to any cause regardless of whether the participant withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization + 1). The OS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on HPV status (OPC HPV positive or HPV-unrelated), WHO/ECOG PS (0 or 1) and number of prior lines of therapy in R/M setting (1 or 2).
| Months | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Overall Survival in Full Analysis Set (FAS) | 8.8 (6.9 to 10.8) | 8.9 (6.0 to 15.1) |
PFS per RECIST 1.1 as assessed by the investigator is defined as time from randomization until date of RECIST 1.1-defined radiological progressive disease (PD) or death regardless of whether participant withdraws from therapy or received subsequent anticancer therapy prior to progression. PD: at least 20% increase in sum of diameters of target lesions (TLs), taking as reference the smallest sum on study (nadir) and sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing non-TLs (NTLs) or appearance of new lesions. PFS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on WHO/ECOG PS (0/1) and no. of prior lines of therapy in R/M setting.
| Months | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment in HPV-unrelated Analysis Set | 3.6 (3.1 to 3.7) | 3.8 (2.4 to 4.9) |
PFS per RECIST 1.1 as assessed by the investigator is defined as time from randomization until date of RECIST 1.1-defined radiological progressive disease (PD) or death regardless of whether participant withdraws from therapy or received subsequent anticancer therapy prior to progression. PD: at least 20% increase in sum of diameters of target lesions (TLs), taking as reference the smallest sum on study (nadir) and sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. PFS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on HPV status, WHO/ECOG PS (0/1) and no. of prior lines of therapy in R/M setting.
| Months | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Progression-Free Survival Per RECIST 1.1 by Investigator Assessment in FAS | 3.5 (2.3 to 3.7) | 3.7 (2.2 to 4.2) |
The OR is defined as the percentage of participants with at least one confirmed investigator-assessed response of complete response (CR) or partial response (PR) as assessed by RECIST 1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. Participants who had measurable disease at baseline per the site investigator were analyzed for this outcome.
| Percentage of Participants | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Percentage of Participants With Objective Response (OR) Per RECIST 1.1 in HPV-unrelated Analysis Set | 15.2 (0.274 to 1.154) | 23.9 |
The OR is defined as the percentage of participants with at least one confirmed investigator-assessed response of CR or PR as assessed by RECIST 1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. Participants who had measurable disease at baseline per the site investigator were analyzed for this outcome.
| Percentage of Participants | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Percentage of Participants With OR Per RECIST 1.1 in FAS | 13.1 (0.297 to 1.231) | 19.1 |
The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as at least a 30% decrease in the SoDs of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in the SoDs of TLs, taking as reference the smallest previous SoDs (nadir) and the sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. The DoR was analyzed using Kaplan-Meier technique.
| Months | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Duration of Response (DoR) Per RECIST 1.1 in HPV-unrelated Analysis Set | 5.7 (5.5 to 8.1) | 5.6 (4.4 to NA) |
The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as at least a 30% decrease in the SoDs of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in the SoDs of TLs, taking as reference the smallest previous SoDs (nadir) and the sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. The DoR was analyzed using Kaplan-Meier technique.
| Months | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Duration of Response Per RECIST 1.1 in FAS | 5.7 (5.3 to 8.1) | 5.6 (4.4 to NA) |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.
| Participants | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 236 | 120 |
Participants with abnormal laboratory parameters reported as TEAEs are reported. Laboratory analysis included hematology and clinical chemistry. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.
| Participants | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Anaemia | 35 | 15 |
| Anaemia folate deficiency | 1 | 0 |
| Hypochromic anaemia | 1 | 0 |
| Iron deficiency anaemia | 1 | 0 |
| Leukocytosis | 3 | 2 |
| Leukopenia | 0 | 1 |
| Lymphocytosis | 0 | 1 |
| Lymphopenia | 3 | 1 |
| Neutropenia | 1 | 1 |
| Neutrophilia | 0 | 2 |
| Normocytic anaemia | 1 | 0 |
| Thrombocytopenia | 1 | 0 |
| Thrombocytosis | 1 | 2 |
| Hyperthyroidism | 0 | 1 |
| Hypoparathyroidism | 1 | 0 |
| Hypothyroidism | 15 | 7 |
| Hyperamylasaemia | 1 | 0 |
| Hypercalcaemia | 7 | 4 |
| Hyperglycaemia | 7 | 5 |
| Hyperkalaemia | 3 | 1 |
| Hyperlipasaemia | 1 | 0 |
| Hypermagnesaemia | 3 | 1 |
| Hyperphosphataemia | 1 | 0 |
| Hypoalbuminaemia | 2 | 4 |
| Hypocalcaemia | 11 | 4 |
| Hypoglycaemia | 1 | 0 |
| Hypokalaemia | 13 | 9 |
| Hypomagnesaemia | 42 | 21 |
| Hyponatraemia | 6 | 3 |
| Hypophosphataemia | 9 | 8 |
| Iron deficiency | 1 | 0 |
| Activated partial thromboplastin time prolonged | 1 | 0 |
| Alanine aminotransferase increased | 7 | 5 |
| Amylase increased | 6 | 3 |
| Aspartate aminotransferase increased | 7 | 4 |
| Blood alkaline phosphatase increased | 7 | 3 |
| Blood beta-D-glucan increased | 0 | 1 |
| Blood bilirubin increased | 3 | 0 |
| Blood creatine phosphokinase increased | 2 | 0 |
| Blood creatinine increased | 6 | 3 |
| Blood iron decreased | 0 | 1 |
| Blood lactate dehydrogenase increased | 3 | 3 |
| Blood phosphorus decreased | 1 | 0 |
| Blood potassium decreased | 1 | 0 |
| Blood thyroid stimulating hormone abnormal | 1 | 0 |
| Blood thyroid stimulating hormone increased | 2 | 3 |
| Blood urea increased | 0 | 1 |
| C-reactive protein increased | 0 | 2 |
| Gamma-glutamyltransferase increased | 5 | 1 |
| Inflammatory marker increased | 1 | 0 |
| International normalised ratio increased | 1 | 0 |
| Lipase increased | 12 | 2 |
| Lymphocyte count decreased | 3 | 0 |
| Neutrophil count decreased | 2 | 3 |
| Neutrophil count increased | 1 | 0 |
| Platelet count decreased | 1 | 0 |
| Platelet count increased | 1 | 0 |
| Transaminases increased | 1 | 0 |
| White blood cell count decreased | 2 | 3 |
| White blood cell count increased | 1 | 0 |
| Dyslipidaemia | 0 | 1 |
Participants with abnormal vital signs (heart rate, blood pressure, temperature, and respiratory rate) reported as TEAEs are reported. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.
| Participants | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Hypertension | 4 | 4 |
| Hypotension | 11 | 3 |
| Hypoxia | 0 | 1 |
| Hyperpyrexia | 1 | 0 |
| Pyrexia | 18 | 10 |
Participants with Abnormal ECGs reported as TEAEs are reported. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.
| Participants | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Electrocardiogram QT prolonged | 1 | 0 |
| Arrhythmia | 0 | 1 |
| Atrial fibrillation | 1 | 0 |
| Sinus tachycardia | 2 | 0 |
| Tachycardia | 2 | 2 |
| Ventricular arrhythmia | 0 | 1 |
Collected over Day 1 through 21.4 months (maximum observed duration). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | 120/247 (48.6%) | 77/246 (31.3%) | 213/246 (86.6%) |
| Placebo Q2W + Cetuximab 400 mg/m^2 | 61/123 (49.6%) | 27/122 (22.1%) | 111/122 (91%) |
| Event | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| PneumoniaInfections and infestations | 13/246 | 8/122 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/246 | 3/122 |
| Covid-19Infections and infestations | 5/246 | 1/122 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/246 | 2/122 |
| PyrexiaGeneral disorders | 4/246 | 0/122 |
| SepsisInfections and infestations | 4/246 | 0/122 |
| StomatitisGastrointestinal disorders | 3/246 | 0/122 |
| Pneumonia aspirationInfections and infestations | 3/246 | 1/122 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/246 | 0/122 |
| Venous thrombosisVascular disorders | 0/246 | 1/122 |
| Event | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 |
|---|---|---|
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 80/246 | 42/122 |
| RashSkin and subcutaneous tissue disorders | 56/246 | 27/122 |
| FatigueGeneral disorders | 48/246 | 20/122 |
| HypomagnesaemiaMetabolism and nutrition disorders | 42/246 | 20/122 |
| NauseaGastrointestinal disorders | 26/246 | 20/122 |
| ParonychiaInfections and infestations | 28/246 | 19/122 |
| PruritusSkin and subcutaneous tissue disorders | 32/246 | 18/122 |
| AnaemiaBlood and lymphatic system disorders | 33/246 | 15/122 |
| ConstipationGastrointestinal disorders | 33/246 | 11/122 |
| StomatitisGastrointestinal disorders | 31/246 | 16/122 |
Baseline analysis population included all participants randomized up to the safety DCO date of 01Sep2022.
| Age, Continuous(Years) | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 | Total |
|---|---|---|---|
| Mean | 62.0 ± 10.4 | 61.4 ± 9.6 | 61.8 ± 10.1 |
| Sex: Female, Male(Participants) | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 | Total |
|---|---|---|---|
| Female | 42 | 29 | 71 |
| Male | 205 | 94 | 299 |
| Ethnicity (NIH/OMB)(Participants) | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 5 | 17 |
| Not Hispanic or Latino | 223 | 114 | 337 |
| Unknown or Not Reported | 12 | 4 | 16 |
| Race (NIH/OMB)(Participants) | Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 | Placebo Q2W + Cetuximab 400 mg/m^2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 66 | 30 | 96 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 169 | 89 | 258 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 9 | 4 | 13 |
Showing the first 100 of 127 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of the timelines, please refer to the disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2020 to primary completion in May 2022, 19 months.
Results were first posted in Nov 2023, 1 year 6 months after primary completion. A results delay was requested in May 2023.
Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Monalizumab
Squamous Cell Carcinoma of Head and Neck →